FDA Gives OK For Psoriasis Clinical Trial for CF101 Phase 3

The company is located in Israel with an office here in the US in Waltham, Massachusetts. Most drugs that are available for treating psoriasis are expensive biotech drugs and the company is attempting to create a drug that will be affordable and it is also showing a response to Dry Eye Syndrome and Rheumatoid arthritis.

With moving into phase 3 and 300 participants in the trial both here and in Israel perhaps this one will move along quickly as this is an anti-inflammatory drug. This would be a pill that you would take and not a topical application. BD

FDA officials were satisfied with earlier trials of CF101 for the treatment of psoriasis.

Can-Fite BioPharma Ltd. (TASE:CFBI) has obtained US Food and Drug Administration (FDA) approval for a phase II/III clinical trial of CF101 for the treatment of the skin disease psoriasis. The trial follows the successful results of the phase II and safety and effectiveness trials and meetings between company officials and the FDA on the Investigational New Drug (IND) Application.

FDA officials were satisfied with the preclinical and clinical trials of CF101 for the treatment of psoriasis, as well as from the results of the safety trial and detailed report that Can-Fite submitted.

The new trial, which will begin in a few months, will include 300 patients in Israel, Europe, and the US.

Can-Fite says that psoriasis affects 2-3% of the population, and estimates the global market for treatment at $3.5 billion a year. Most current treatments are expensive biological drugs, which also have the characteristic side effects of these drugs.